EGFR and neoplasm: The FDG-PET imaging reveals that both ZR2002 and JS84 were able to statistically reduce the total glycolytic activity (TLG parameter, Figure 3C), and we speculate that the inhibition of the EGFR signaling pathway may have interfered indirectly with the reduction in the glycolytic pathway, decelerating the tumor proliferation.